Formulation and Evaluation of Lornoxicam Nanosuspension with Eudragit Rs100 Polymer

Abstract

BCS Class II has a low aqueous solubility problem in pharmaceutical formulation. Hence to overcome this problem this research the was carried out for BCS Class II drug lornoxicam was selected to enhance the aqueous solubility by formulating nanosuspension with a polymer like Eudragit RL100, Eudragit RS100 and Poloxamber407 as a stabilizer. The present study focuses on the polymer Eudragit RS100. A total of four formulations LRS-F1, LRS-F2, LRS-F3, LRS-F4, and LRS-F4 were prepared with a ratio of drug: polymer: stabilizer (1:1:0.5 & 1:2:0.5, 1:1:1 & 1:2:1)LRS-F4 formulation was found to be optimized formulation with  90.00 – 100 nm particle size & -11.20 zeta potential and % drug release at the end of 10 hrs was found to be 96.88 % with the increase in the dissolution/saturation solubility of 70.36±0.09 ( µg /mL) of poorly water-soluble lornoxicam (reported solubility with 14.28 µg /mL µg /mL). The amount unincorporated was found to be 09.74 % with an optimized formulation. Moreover, the physical appearance of the nanosuspension was found to be up to the mark confirming that the nanosuspension is stable and has no crystal growth or crystal development with optimized formulation at a temperature of 4 °C for 3 months. Poloxamer 407 as a stabilizer.